Name

Dexa-BEAM

Alternate names

None

Primary Site

None

Histology

None

Radiation

None

Remarks

None

Drugs for Dexa-BEAM

Name

Alternate Names

Dom-Etoposide
Epipodophyllotoxin derivative
Epipodophyllotoxin ethylidene gluco-pyranoside
Eposine
Ethylidene-Lignan P
Etopophos
Podophyllotoxin derivative
Vepesid
VP 16-213
VP-16
VP-16213
Toposar

Abbreviations

EPEG
VP-16
VP-16-213

Category

Chemotherapy

Subcategory

Epipodophyllotoxin, topoisomerase II inhibitor
Plant alkaloid

NSC Number

141540

Primary Site

Gastric cancer
Hodgkins lymphoma
Lung cancer (NSCLC, SCLC)
Non-Hodgkin lymphoma
testicular cancer (Germ cell tumors)

Histology

None

Remarks

Plant alkaloid. FDA approved use on small-cell lung cancer, testicular cancer.

Coding

This drug should be coded

Name

Alternate Names

Aeroseb-Dex
AK-Dex
AK-Trol
Baldex
Component of Deronil
Component of Dexacidin
Component of Maxitrol
Dalalone
Decaderm
Decadrol
Decadron Tablets
Decajet
Decameth
Decasone
Decaspray
Deenar
Dex-4
Dexacen
Dexacidin
Dexacort Phosphate
Dexameth
Dexasone
Dexasporin
Dexone
Dexsone
Dezone
Gammacorten
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Infectrol Sterile
Maxidex
Maxitrol
Miral
Mymethasone
Neo-Dexameth
Neodecadron
Neodexair
Ocu-Trol
Oradexon
PMS-Dexamethasone Sodium Phosphate
SK-Dexamethasone
Sofracort
Sofradex
Solurex
Spersadex
Sterile Dexamethasone Acetate
Tobradex
Turbinare Decaron Phosphate

Abbreviations

DECA
DM
DSM

Category

Ancillary Agent
Hormones and hormonal mechanisms

Subcategory

Glucocorticoid. Probably not cancer directed--verify with attending MD.

NSC Number

345211

Primary Site

None

Histology

None

Remarks

NOTE* Dexamethosine may be coded as either an ancillary drug or hormone. Review chart to determine if given for supportive care or as hormonal therapy.

A long-acting corticosteroid (glucocorticoid). In general, this drug is used more commonly for supportive care, and as an antiemetic than it is as hormone therapy. 25 times as potent as cortisol; used topically as an anti-inflammatory and administered orally in replacement therapy for adrenal insufficiency, as an anti-inflammatory and immunosuppressant in a wide variety of disorders, and as an antiemetic in cancer chemotherapy. Dexamethasone and other corticosteroids may be used to control white cell proliferation in hematopoietic diseases and would be coded as hormone therapy for lymphoid leukemia, lymphoma and multiple myeloma.

Coding

Please see remarks for additional information

Name

Alternate Names

Alanine mustard
Alkeran
CB-3025
DL Sarcolysine
DL-O-Sarcolysin
L-Phenylalanine Mustard
L-Sarcolysin
Melfalan
Phenylalanine Mustard
Sarcolysine
Sarkoklorin
Sarkolizin
WR-19813

Abbreviations

L-PAM
MPL
PAM

Category

Chemotherapy

Subcategory

Alkylating agent

NSC Number

8806
008806
57199

Primary Site

Multiple myeloma
ovarian cancer
Polycythemia Vera

Histology

None

Remarks

Alkylating antineoplastic agent. FDA approved uses on multiple myeloma and epithelial non-resectable ovarian carcinoma.
Also used in the high-dose chemotherapy and transplant setting.
Mechanism of action: Analog of nitrogen mustard

Coding

This drug should be coded

Name

Alternate Names

AC-1075
Alexan
Ara-cytidine
Arabinocytidine
Arabinosylcytosine
Beta-Arabinosylcytosine
Cytarabin
Cytarabine
Cytarabinoside
Cytosar
Cytosar-U
Cytosine Arabinoside
Cytosine arabinoside hydrochloride
Spongocytidine HCL
Tarabine
Tarabine PFS
U-19920
U-19920A
WR-28453

Abbreviations

ara-C
CA
HDA
HDARA-C

Category

Chemotherapy

Subcategory

Antimetabolite

NSC Number

063878
63878

Primary Site

ALL
AML
CML
head and neck
Hodgkin's disease
leukemia
Meningeal leukemia
NHL

Histology

None

Remarks

Antineoplastic agent; antimetabolite. FDA approved uses on Hodgkin's disease, leukemia; under investigation for Rx of Progressive Multifocal Leukoencephalopathy (PML)

Coding

This drug should be coded

Name

Alternate Names

BiCNU
Carmustinea
DTI 015
DTI-015
DTI015
WR 139021
WR-139021
WR139021

Abbreviations

BCNU

Category

Chemotherapy

Subcategory

Alkylating agent

NSC Number

409962

Primary Site

Brain
Hodgkin Lymphoma
Kidney cancer
Multiple myeloma
Non-Hodgkin lymphoma

Histology

None

Remarks

Phase I FDA approved uses on brain tumor, Hodgkin's lymphoma, non-Hodgkin's lymphoma, multiple myeloma. Guilford Pharmaceuticals.(nitrosourea) (alkylating agent)

Coding

This drug should be coded
Glossary